JP2019533672A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533672A5
JP2019533672A5 JP2019519420A JP2019519420A JP2019533672A5 JP 2019533672 A5 JP2019533672 A5 JP 2019533672A5 JP 2019519420 A JP2019519420 A JP 2019519420A JP 2019519420 A JP2019519420 A JP 2019519420A JP 2019533672 A5 JP2019533672 A5 JP 2019533672A5
Authority
JP
Japan
Prior art keywords
mini
melatonin
tablet
controlled release
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019519420A
Other languages
English (en)
Japanese (ja)
Other versions
JP6830156B2 (ja
JP2019533672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/057190 external-priority patent/WO2018078429A1/en
Publication of JP2019533672A publication Critical patent/JP2019533672A/ja
Publication of JP2019533672A5 publication Critical patent/JP2019533672A5/ja
Application granted granted Critical
Publication of JP6830156B2 publication Critical patent/JP6830156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019519420A 2016-10-31 2016-11-29 メラトニンミニタブレットおよびその製造方法 Active JP6830156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415014P 2016-10-31 2016-10-31
US62/415,014 2016-10-31
PCT/IB2016/057190 WO2018078429A1 (en) 2016-10-31 2016-11-29 Melatonin mini-tablets and method of manufacturing the same

Publications (3)

Publication Number Publication Date
JP2019533672A JP2019533672A (ja) 2019-11-21
JP2019533672A5 true JP2019533672A5 (cg-RX-API-DMAC7.html) 2020-01-09
JP6830156B2 JP6830156B2 (ja) 2021-02-17

Family

ID=57482481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519420A Active JP6830156B2 (ja) 2016-10-31 2016-11-29 メラトニンミニタブレットおよびその製造方法

Country Status (25)

Country Link
US (2) US10722494B2 (cg-RX-API-DMAC7.html)
EP (3) EP3337462B1 (cg-RX-API-DMAC7.html)
JP (1) JP6830156B2 (cg-RX-API-DMAC7.html)
KR (1) KR102167190B1 (cg-RX-API-DMAC7.html)
CN (1) CN109922795B (cg-RX-API-DMAC7.html)
AU (6) AU2016426598C1 (cg-RX-API-DMAC7.html)
CA (1) CA3040027C (cg-RX-API-DMAC7.html)
CY (1) CY1123449T1 (cg-RX-API-DMAC7.html)
DK (2) DK3337462T3 (cg-RX-API-DMAC7.html)
ES (2) ES3009413T3 (cg-RX-API-DMAC7.html)
FI (1) FI3777842T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20250166T1 (cg-RX-API-DMAC7.html)
HU (2) HUE051362T2 (cg-RX-API-DMAC7.html)
IL (1) IL262537B (cg-RX-API-DMAC7.html)
LT (2) LT3777842T (cg-RX-API-DMAC7.html)
MX (1) MX386987B (cg-RX-API-DMAC7.html)
NZ (1) NZ747702A (cg-RX-API-DMAC7.html)
PL (2) PL3777842T3 (cg-RX-API-DMAC7.html)
PT (2) PT3337462T (cg-RX-API-DMAC7.html)
RS (2) RS66471B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201903829PA (cg-RX-API-DMAC7.html)
SI (2) SI3337462T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202000575T1 (cg-RX-API-DMAC7.html)
TW (1) TWI787164B (cg-RX-API-DMAC7.html)
WO (1) WO2018078429A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125733A1 (en) * 2020-10-23 2022-04-28 Atoz Pharmaceuticals Pvt Ltd Nongranulated compressed tablets of mesalamine, and process of preparation thereof
WO2022092767A1 (ko) * 2020-10-26 2022-05-05 일동제약(주) 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제
AU2023359918A1 (en) 2022-10-14 2025-03-27 Société des Produits Nestlé S.A. Sustained release melatonin compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
DK0518468T3 (da) 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
IL105240A (en) 1992-04-07 1999-04-11 Neurim Pharma 1991 The use of melatonin in the preparation of a drug for the treatment of benign prostatic hyperplasia
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
WO1995003043A1 (en) * 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
WO1996023496A1 (en) * 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
TR200201724T2 (tr) 2000-01-05 2003-03-21 Neurim Pharmaceuticals (1991) Ltd. Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
KR20030016215A (ko) * 2002-07-05 2003-02-26 뉴림 파머슈티칼스 (1991) 리미티드 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
WO2005063297A2 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
WO2008148015A1 (en) 2007-05-24 2008-12-04 The Trustees Of Columbia University In The City Of New York Sustained release formulation of melatonin
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
DK2949322T3 (en) 2014-05-28 2018-07-23 Valpharma S P A FORMULATION FOR ORAL ADMINISTRATION COMPREHENSIVE MELATONIN IN STABLE FORM AND PROCEDURE FOR PREPARING THEREOF

Similar Documents

Publication Publication Date Title
ES2865278T3 (es) Amantadina para mejorar la marcha en esclerosis múltiple
JP2009537548A (ja) ウイルス感染症の治療のための方法および組成物
JP2020500864A5 (cg-RX-API-DMAC7.html)
US11166931B2 (en) Induction of arteriogenesis with an NO (nitric oxide) donor
JP2019533672A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
KR20090045149A (ko) 류마티스 질환의 지연-방출형 글루코코르티코이드 치료제
HRP20201722T1 (hr) Minitablete melatonina i postupak njihove proizvodnje
JP2011506607A5 (cg-RX-API-DMAC7.html)
TW201739455A (zh) 菸鹼醯胺的口服醫藥組成物
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
US9675552B2 (en) Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
JP6420923B1 (ja) 医薬
JP2018502168A5 (cg-RX-API-DMAC7.html)
CN104906063A (zh) 一种新型复方安眠控释制剂的释放方式及其制备方法
TWI744858B (zh) 治療精神疾病之控釋藥物組合物和方法
RU2013124994A (ru) КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
NZ782840B2 (en) Melatonin mini-tablets and method of manufacturing the same
CN112843053B (zh) Ns5a抑制剂组合物
EP2854794B1 (en) Stabilized granules containing glyceryl trinitrate for inducing arteriogenesis
FI4065134T3 (fi) Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta
Sundaravel et al. Methylene blue to the rescue in accidental treprostinil overdose
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
CN112843013A (zh) 治疗丙型肝炎的组合物及其制备方法
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada